Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Gian Life Care Ltd approved unaudited standalone and consolidated financial results for Q3 FY26 (quarter ended December 31, 2025) on February 14, 2026. Revenue from operations fell sharply to Rs. 112.28 lakhs in Q3 FY26 from Rs. 158.86 lakhs in Q3 FY25, a decline of about 29%. For the nine months ended December 2025, revenue collapsed to Rs. 264.98 lakhs from Rs. 551.76 lakhs (a ~52% drop), and the company swung to a standalone loss of Rs. 28.54 lakhs versus a profit of Rs. 63.18 lakhs in the prior year period. The auditor (MSNT & Associates LLP) issued a qualified review report, flagging that a cash balance of Rs. 743.78 lakhs could not be independently verified, while statutory dues of Rs. 426.66 lakhs and a bank loan of Rs. 359.78 lakhs (classified as a Non-Performing Asset) remained unpaid.
Negative for shareholders — sharp revenue erosion, a return to losses, an NPA-tagged bank loan, and an auditor qualified review raise serious concerns about liquidity and going-concern status. Expect negative sentiment on the stock.